Industry practice has changed radically over the past five decades. Can laws published in the 1960s still ensure pharmaceutical quality and safety today?
The biopharmaceutical industry has undergone major changes since GMPs were last updated in 1977. However, FDA says it has no plans for any major revisions of cGMPs. Industry experts argue, however, that changes are needed in Training and employee personal development, statistics and sampling, and process validation.
Read this article in BioPharm International’s September 2019 Regulatory Sourcebook.
BioPharm International
eBook: Regulatory Sourcebook, September 2019
September 2019
Pages: 10–13
When referring to this article, please cite it as A. Shanley, “Is it Time to Update cGMPs?" BioPharm International Regulatory Sourcebook eBook (September 2019).
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.